What is Vaxcyte, Inc.'s PP&E (net)?

Vaxcyte, Inc. (PCVX) reported PP&E (net) of $260.7M in Q1 2026.

How has Vaxcyte, Inc.'s PP&E (net) changed year-over-year?

Vaxcyte, Inc.'s PP&E (net) increased by 20.1% year-over-year, from $217.16M to $260.7M.

What is the long-term trend for Vaxcyte, Inc.'s PP&E (net)?

Over 5 years (2020 to 2025), Vaxcyte, Inc.'s PP&E (net) has grown at a 139.4% compound annual growth rate (CAGR), from $3.27M to $257.37M.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Vaxcyte, Inc. (PCVX) PP&E (Net) — Quarterly & Annual

Screener

PP&E (Net) at other companies

PfizerPFE

$19.4B+5.8%

Merck & Co.MRK

$25.43B+2.6%

ModernaMRNA

$2.06B-5.1%

NovavaxNVAX

$38.13M-70.6%

Krystal Biotech, Inc.KRYS

$153.58M+1.7%

RegenxbioRGNX

$98.45M-11.3%

Segments

By geography

See full

SWITZERLAND$219.4M+24.2%

UNITED STATES$41.3M+2.0%

Other financials

Income statement

See full

Operating income-$345.9M-91.3%

Net income-$320.6M-128%

EPS (diluted)-$2.30-121%

Balance sheet

See full

Cash & equivalents$262.3M-24.7%

Total debt$116.3M+33.5%

Total equity$3.0B-6.4%

Total assets$3.3B-0.9%

Cash flow

See full

Operating cash flow-$280.6M-68.8%

CapEx$2.1M-61.2%

Free cash flow-$282.7M-64.7%

Valuation

See full

Market cap$8.07B+89.7%

Enterprise value$7.93B+96.5%

Returns & leverage

See full

Return on equity-30.6%+37.9pp

Debt / equity0×0.0×

Current ratio7.5×-10.2×

Where this comes from

Reported directly by Vaxcyte, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.

Filed: May 6, 2026, 4:12 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001649094-26-000017

Line item	March 31,2026	December 31, 2025
Short-term investments	1,476,335	1,387,000
Prepaid expenses and other current assets	76,310	66,402
Total current assets	1,813,488	1,627,361
Property and equipment, net	260,695	257,370
Operating lease right-of-use assets	113,103	116,009
Long-term investments	1,004,017	881,664
Restricted cash	1,466	1,466
Other assets	155,539	118,847

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Vaxcyte, Inc.'s PP&E (net)?: Vaxcyte, Inc. (PCVX) reported PP&E (net) of $260.7M in Q1 2026.
How has Vaxcyte, Inc.'s PP&E (net) changed year-over-year?: Vaxcyte, Inc.'s PP&E (net) increased by 20.1% year-over-year, from $217.16M to $260.7M.
What is the long-term trend for Vaxcyte, Inc.'s PP&E (net)?: Over 5 years (2020 to 2025), Vaxcyte, Inc.'s PP&E (net) has grown at a 139.4% compound annual growth rate (CAGR), from $3.27M to $257.37M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.